The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The order will cover the manufacturing of bulk vaccine in 2026
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
Subscribe To Our Newsletter & Stay Updated
